Alzheimer’s play­er AC Im­mune taps IPO for $58M raise, sees shares soar

Swiss biotech AC Im­mune fol­lowed through on its IPO $ACIU to­day, pric­ing at $11 a share . That’s the low end of the range, but the com­pa­ny bumped the net to $58 mil­lion by adding 1.5 mil­lion shares, in­creas­ing the to­tal to 6 mil­lion.

The big pay­off came af­ter the open on Fri­day, though, as the biotech’s shares rock­et­ed up 42% on its de­but.

AC Im­mune has been a promi­nent play­er in Alzheimer’s, one of the tough­est games in biotech. Backed in part by bil­lion­aire Di­et­mar Hopp, the biotech is part­nered with Roche on crenezum­ab, now ad­vanced in­to a piv­otal study af­ter mixed re­sults in an ear­li­er study.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER